Rybrevant Faspro (Amivantamab and Hyaluronidase-lpuj)

Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated:

• in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
• in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.
• in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation.
• as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

Recommended Dosage:
Rybrevant Faspro has different recommended dosage and administration than intravenous amivantamab products. Administer each injection subcutaneously in the abdomen over approximately 5 minutes. The recommended dosage of Rybrevant Faspro is based on baseline body weight. Administer premedications as recommended.
If a dose is missed, it should be given as quickly as possible within the recommended time. For the 4-week or 2-week schedule, missed doses during the first 4 weeks should be given within 24 hours, and from Week 5 onward within 7 days. For the 3-week schedule, missed doses during the first 3 weeks should be given within 24 hours, and from Week 4 onward within 7 days. If the missed dose is not given within these time limits, skip the missed dose and continue with the next dose as per the regular schedule.

• Monitor patients closely during and after administration for hypersensitivity and infusion-related reactions such as fever, chills, rash, breathing difficulty, or low blood pressure. Interrupt or stop treatment based on severity and provide appropriate supportive care immediately if reactions occur.
• Monitor patients for new or worsening lung symptoms such as cough, shortness of breath, or fever. Withhold treatment if interstitial lung disease or pneumonitis is suspected and permanently discontinue if confirmed after evaluation and no other cause is identified.
• Patients receiving Rybrevant Faspro with lazertinib may have an increased risk of venous thromboembolic events such as deep vein thrombosis or pulmonary embolism. Monitor for symptoms like swelling, chest pain, or breathlessness and manage promptly with appropriate treatment.
• Monitor for skin-related side effects including rash, dry skin, itching, or severe reactions. Advise patients on proper skin care and sun protection. Adjust dose or interrupt treatment if severe dermatologic reactions occur and provide appropriate medical management as needed.
• Patients may experience eye problems such as dryness, irritation, redness, or vision changes. Monitor for symptoms and advise patients to report any eye discomfort. Refer to an eye specialist if needed and manage with supportive care or treatment adjustments.
• Rybrevant Faspro may cause harm to an unborn baby when used during pregnancy. Advise women of childbearing potential to use effective contraception during treatment and for a specified period after the last dose to avoid potential risk to the fetus.
• It is not known whether Rybrevant Faspro passes into human milk or affects a breastfed child. Advise women not to breastfeed during treatment and for a certain period after the last dose to prevent potential harm to the infant.

What documents are required to import RYBREVANT FASPRO to India?

RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is RYBREVANT FASPRO available in India?

Rybrevant Faspro (amivantamab and hyaluronidase-lpuj injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Rybrevant Faspro in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Rybrevant Faspro price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

RYBREVANT FASPRO can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, as well as other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of RYBREVANT FASPRO (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please WhatsApp +91 98104 69557 | Toll-Free Number: 1800-1200-365 or write us at info@indianpharmanetwork.in for the Rybrevant Faspro cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source RYBREVANT FASPRO (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Rybrevant Faspro®?

Amivantamab and hyaluronidase-lpuj is the Generic Name for the trade name drug Rybrevant Faspro®.

What is the Manufacturer’s Name of Rybrevant Faspro®?

Rybrevant Faspro® is manufactured by Janssen Biotech, Inc.

Is Rybrevant Faspro approved by the FDA?

Yes. Rybrevant Faspro is approved by the FDA. Date of first approval: December 17, 2025.

What is the dosage and form of Rybrevant Faspro® supplied?

Rybrevant Faspro is supplied for Injection: 1,600 mg amivantamab and 20,000 units hyaluronidase per 10 mL (160 mg and 2,000 units/mL) solution in a single-dose vial for subcutaneous use.

What are the most common side effects of Rybrevant Faspro® injection?

The most commonly reported side effects of Rybrevant Faspro®:

• in Combination with Lazertinib: rash, nail toxicity, musculoskeletal pain, fatigue, stomatitis, edema, nausea, diarrhea, vomiting, constipation, decreased appetite, and headache.
• Intravenous Amivantamab in Combination with Lazertinib: rash, nail toxicity, dry skin, infusionrelated reaction, edema, musculoskeletal pain, stomatitis, VTE, paresthesia, constipation, fatigue, diarrhea, COVID-19, hemorrhage, decreased appetite, pruritus, and nausea.
• Intravenous Amivantamab in Combination with Carboplatin and Pemetrexed: rash, fatigue, nausea, nail toxicity, infusionrelated reaction, stomatitis, constipation, edema, vomiting, decreased appetite, musculoskeletal pain, and COVID-19.
• Intravenous Amivantamab as a Single Agent: rash, infusion-related reaction, fatigue, paronychia, musculoskeletal pain, dyspnea, edema, cough, stomatitis, nausea, constipation, vomiting, and pruritus.

How does Rybrevant Faspro Import in India work?

Rybrevant Faspro Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

Who is a reliable Rybrevant Faspro supplier in India?

Indian Pharma Network is a trusted Rybrevant Faspro supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.

How much does Rybrevant Faspro® injection cost in India?

Rybrevant Faspro® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Rybrevant Faspro prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Rybrevant Faspro cost in India, please call +91 96548 60915 or WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Rybrevant Faspro® injection be available in SAARC countries?

Apart from Gulf countries, Rybrevant Faspro® injection can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Rybrevant Faspro® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Rybrevant Faspro® injection online in India?

Yes, one can buy Rybrevant Faspro in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Rybrevant Faspro® injection through legal channels.

Who is an authorized Rybrevant Faspro importer in India?

Indian Pharma Network acts as an Rybrevant Faspro importer in India, assisting with Named Patient import processes, regulatory documentation, and compliant international procurement for patients requiring this therapy.

What are the storage conditions of Rybrevant Faspro® injection?

Store the vials in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F) in original carton to protect from light. It is not advisable to freeze or shake the vials.